Summary & Overview
HCPCS J0791: Injection, crizanlizumab-tmca, 5 mg
HCPCS Level II code J0791 designates a 5 mg injection of crizanlizumab-tmca, a biologic therapy used in specialized outpatient infusion settings. This code matters nationally as it standardizes reporting and billing for administration of an intravenous biologic product, affecting coverage decisions, reimbursement pathways, and utilization monitoring across commercial and public payers. Key payers considered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will learn the clinical and administrative context for J0791, including the typical sites of service and how the code is used in claims. The publication outlines benchmarks and policy-relevant issues that influence coverage and payment, summarizes common modifier use where available, and highlights implications for facility billing and payer authorization processes. The content provides a concise reference for revenue cycle, clinical administration teams, and policy analysts seeking clarity on coding and billing practices for crizanlizumab-tmca injections at the national level.
Billing Code Overview
HCPCS Level II code J0791 represents an injection of crizanlizumab-tmca, 5 mg. This HCPCS code corresponds to a biologic infusion product provided as an intravenous injection. The service type is an injectable biologic therapy administered by infusion or injection. The typical site of service is an outpatient infusion center or hospital outpatient department where biologic infusions are commonly delivered. Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult or adolescent with sickle cell disease experiencing recurrent vaso-occlusive crises. The patient is seen in an outpatient infusion clinic or hospital outpatient department for administration of a disease-modifying monoclonal antibody, crizanlizumab-tmca, marketed as a single-agent intravenous infusion dosed in mg. The workflow begins with a hematology consultation documenting indication and baseline vitals, medication reconciliation and allergy check, eligibility confirmation (including prior authorization if required by the payer), and establishment of vascular access (peripheral IV or existing port). Nursing performs pre-infusion assessment, prepares the reconstituted drug per manufacturer instructions, and administers the intravenous infusion over the recommended time with monitoring for infusion reactions. Post-infusion observation is documented, adverse events are recorded, and claims are submitted using billing code J0791 for the drug with the appropriate units and any applicable modifiers. Typical sites of service include outpatient infusion centers, hospital outpatient departments, and specialty clinic infusion rooms. Payors involved commonly include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JZ | Drug administered was not partially discarded | Use when the full single-use vial(s) were administered with no discarded portion billed. |